Novo Nordisk to Halve Wegovy's US List Price as Competition Bites

What Happened

Novo Nordisk has announced it will cut the US list price of Wegovy by 50% — to $675 a month, effective January 1, 2027, from roughly $1,350 today — alongside a 35% reduction for Ozempic, with the oral Rybelsus moving to the same $675 level. The decision applies to all doses of the affected medicines, the Danish drugmaker said in a statement this week.

The repricing is the sharpest single move yet in the obesity-drug market. Jamey Millar, executive vice president of Novo Nordisk's US operations, framed the cut as an affordability decision aimed at "more than 100 million people living with obesity and over 35 million people with type 2 diabetes in the United States."

The competitive backdrop explains the timing. Eli Lilly's tirzepatide has been taking market share, oral GLP-1 tablets have begun reshaping the market, and the shortage-era window that allowed compounded copies of semaglutide has closed. Novo's injected products still appeared on the FDA's drug-shortage list as of this week's reporting, even as the company repositions on price.

Who Is Affected

• Cash-paying US patients — list price is not net price, but for self-pay buyers the halving of Wegovy's sticker price is direct.
• Insurers and pharmacy-benefit managers — list-price cuts interact with rebate structures; the net effect on spending will take quarters to resolve.
• Compounding and gray-market sellers — the price umbrella that made unregulated semaglutide attractive is visibly shrinking.
• Researchers sourcing semaglutide — as legal access improves, one of the main demand drivers for "research use only" vials weakens.

Timeline

• 2024-2025 — shortage conditions let compounders sell semaglutide copies at deep discounts, training the market on low prices.
• 2026 — Lilly's oral GLP-1 wins approval; Novo follows with its own tablet; competition compresses the injectable franchise.
• This week — Novo announces the 50% Wegovy list-price cut, effective for all doses.
• January 1, 2027 — the new $675 list prices take effect.

What This Means for Researchers

• The gray-market arbitrage is decaying from both ends: regulators closed the shortage loophole, and now the branded list price is halving toward the level compounded sellers once charged.
• Oral GLP-1s cost less to manufacture and ship than cold-chain injectables — expect further price compression as tablets scale, not a stabilization.
• For anyone analyzing peptide market structure, this is the first time a legal channel has repriced toward gray-market levels rather than relying on enforcement alone.
• Demand for unregulated semaglutide does not vanish with a press release, but the economic case weakens — quality-assured supply at halved prices is the most credible counter to "research chemical" sellers the industry has fielded yet.

How to Verify Your Peptides

• How third-party lab testing works
• HPLC versus LC-MS: what each method reveals
• Identity, purity and fill-weight reports explained

Safe Alternatives

• Documented compounds in the research-grade peptide landscape
• Vetted suppliers in the vendor directory

Sources

Company announcements; industry reports.